Syntara FCF Margin

What does Syntara do? Syntara Ltd generates revenue through the development and commercialization of pharmaceutical products targeting blood-related cancers and fibrotic diseases. Its lead candidate PXS-5505 is designed for myelofibrosis, a bone marrow cancer causing blood cell loss, while PXS-4728 serves as an SSAO/MAOB inhibitor for sleep disorders and neurodegenerative diseases. The company also markets Bronchitol for cystic fibrosis and Aridol as a lung function test, focusing on respiratory and fibrotic conditions. These products are developed through Syntara's drug discovery engine centered on amine oxidase inhibitors and pan-LOX inhibitors. The company's primary customers are healthcare providers and patients seeking treatments for myelofibrosis, fibrotic diseases, and respiratory conditions. Syntara's drug candidates target specific medical segments including oncology for blood cancers, neurology for Parkinson's disease progression, and respiratory care for cystic fibrosis. The firm advances its pipeline through clinical-stage development, leveraging its expertise in amine oxidase inhibitors to address unmet medical needs in these therapeutic areas. Syntara Limited, formerly Pharmaxis Ltd, operates as a clinical-stage drug development company with a focus on blood-related cancers. Its product portfolio includes PXS-5505 for myelofibrosis, PXS-4728 for neurodegenerative diseases, Bronchitol for cystic fibrosis, and Aridol for lung function testing. The company's revenue streams derive from the advancement of these drug candidates through clinical trials and potential future commercialization, with no indication of current commercial sales in the provided description. Syntara is one of the most popular companies on Eulerpool.